The Data Just Keeps Getting Better for Pfizer and BioNTech’s COVID-19 Vaccine24/7 Wall Street • 08/21/20
Pfizer, BioNTech Say Second Coronavirus Vaccine Shows Fewer Side Effects Than Their First CandidateBenzinga • 08/21/20
Pfizer and BioNTech's favored Covid-19 vaccine has fewer side effects than their firstCNBC • 08/21/20
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19Business Wire • 08/21/20
Moderna and Other Coronavirus Vaccine Makers to Take Reduced Payments If Approval Milestones Not MetThe Motley Fool • 08/15/20
Is the Options Market Predicting a Spike in BioNTech (BNTX) Stock?Zacks Investment Research • 08/14/20
The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals standCNBC • 08/14/20
BioNTech SE (BNTX) CEO Ugur Sahin on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/12/20
BioNTech and Pfizer Hope to Have Late-Stage Coronavirus Vaccine Results by OctoberThe Motley Fool • 08/11/20
Why Sorrento Therapeutics, Novavax, Moderna, and Other Coronavirus Stocks Plunged TodayThe Motley Fool • 08/11/20
BioNTech Announces Second Quarter 2020 Financial Results and Corporate ProgressGlobeNewsWire • 08/11/20
T Cell Responses To Coronavirus Vaccines Are In The Interest Of National SecuritySeeking Alpha • 08/10/20
BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020GlobeNewsWire • 08/06/20
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine CandidateGlobeNewsWire • 08/05/20
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in ChinaGlobeNewsWire • 08/05/20